PDCD1 and colorectal cancer: Indeed, a recent trial found modest clinical benefit of anti-CCR5 and anti-PD-1 combination on patient with heavily pretreated microsatellite stable colorectal cancer, and more trials are underway to evaluate the safety and efficacy of anti-CCR5 and checkpoint inhibitor combinations (83).